Frontmatter -- List of abbreviations -- Contents -- CHAPTER I. Introduction -- CHAPTER II. Plasma growth hormone suppressive effect of bromocriptine in acromegaly. Evaluation by plasma GH day profiles and plasma GH concentrations during oral glucose tolerance tests / Nortier, J.W.R. / Croughs, R.J.M. / Thijssen, J.H.H. / Schwarz, F. -- CHAPTER III. Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests / Nortier, J.W.R. / Croughs, R.J.M. / Donker, G.H. / Thijssen, J.H.H. / Schwarz, F. -- CHAPTER IV. Bromocriptine therapy in acromegaly: effects on plasma GH levels, somatomedin-C levels and clinical activity / Nortier, J.W.R. / Croughs, R.J.M. / Thijssen, J.H.H. / Schwarz, F. -- CHAPTER V. Gel filtration studies of plasma growth hormone in bromocriptine treated acromegaly: correlations with somatomedin-C and clinical response / Nortier, J.W.R. / Croughs, R.J.M. / Donker, G.H. / Thijssen, J.H.H. / Schwarz, F. -- CHAPTER VI. No acute effect of pimozide on the plasma GH levels in acromegaly / Nortier, J.W.R. / Croughs, R.J.M. / Donker, G.H. / Thijssen, J.H.H. / Schwarz, F. -- CHAPTER VII. Long-term follow-up of five untreated acromegalic patients / Nortier, J.W.R. / Croughs, R.J.M. / Thijssen, J.H.H. / Schwarz, F. -- CHAPTER VIII. General discussion -- Summaryweiterlesen